Third Age Health Services (TAH) Q3 2026 TU earnings summary
Event summary combining transcript, slides, and related documents.
Q3 2026 TU earnings summary
16 Jun, 2026Executive summary
Underlying NPATA for Q3 FY26 reached $979k, up 22.1% year-over-year and down 1.1% sequentially from Q2 FY26.
Services expanded to 119 Aged Residential Care (ARC) facilities, a 35.2% increase year-over-year.
Enrolled patient population grew 3.6% year-over-year to 27,191, including acquisitions; excluding acquisitions, patient numbers declined 1.1%.
Financial highlights
Group revenue for Q3 FY26 was $5,977k, up 23.3% year-over-year and 6.3% over Q2 FY26.
Revenue from ARC-related business rose 34.1% year-over-year to $4,060k and 10.7% over Q2 FY26.
Underlying EBIT for Q3 FY26 was $1,405k, up 19.6% year-over-year and down 3.5% sequentially.
Statutory NPAT increased 16.7% year-over-year to $818k and declined 6.0% from Q2 FY26.
Diluted EPS was 7.30 cents, up 11.6% year-over-year and down 11.6% sequentially.
Outlook and guidance
A fully imputed dividend of 4.00 cents per share declared for Q3 FY26, totaling 12.00 cents per share year-to-date.
Latest events from Third Age Health Services
- NPATA up 36.3% YoY to $1,025k, driven by strong ARC revenue and margin expansion.TAH
Q1 2027 TU - Revenue up 17.9% YoY, underlying NPATA up 25.9%, and total FY26 dividends at 16.00 cents.TAH
H2 2026 - Statutory NPAT surged 236% to $1.38m on 35% revenue growth, with strong ARC expansion.TAH
H2 2024 - Underlying NPATA up 69% and revenue up 26%, with strong growth in ARC and General Practice.TAH
H2 2025 - NPAT up 32% and revenue up 13.2% year-over-year, driven by acquisitions and ARC expansion.TAH
H1 2026 - Strong profit growth and a new fixed dividend policy highlight robust Q1 FY26 performance.TAH
Q1 2026 TU - NPAT up 115% to $1,154k, with strong revenue, margin, and patient growth.TAH
H1 2025 - Revenue and profit surged in Q1 FY25, supported by acquisitions and patient growth.TAH
Q1 2025 TU - Q3 FY25 saw strong profit growth, margin expansion, higher dividends, and robust patient gains.TAH
Q3 2025 TU